Professor Xiaodan Huang  serves as an Associate Chief Physician in the Department of Radiation Oncology and a Master’s Supervisor at the Sun Yat-sen University Cancer Center (SYSUCC) . With a strong academic background, she earned her M.D. from the prestigious eight-year clinical medicine program at Sun Yat-sen University’s Zhongshan School of Medicine. Following her doctoral studies, she completed her postdoctoral training as an Assistant Researcher at SYSUCC from 2019 to 2021.

Professor Huang specializes in the clinical treatment and research of radiation oncology, with a particular focus on gynecological cancers. Her work spans both clinical practice and foundational research, aiming to improve therapeutic outcomes for patients. She has made significant contributions to the field, publishingmore than 10 SCI-indexed papers as the first or co-first author in high-impact journals such as Cell Research, Cell Death and Differentiation, International Journal of Radiation Oncology, Biology, Physics, Radiotherapy and Oncology, and Cancer. Her expertise is also recognized internationally, as she serves as a reviewer for esteemed journals like Cell Death and Disease and Scientific Reports.

In addition to her clinical and research roles, Professor Huang is an active member of the Chinese Anti-Cancer Association, where she holds a position on the Youth Committee of the Brachytherapy Specialty Committee. She has led several important research projects, including the National Natural Science Foundation of China Youth Project and the China Postdoctoral Science Foundation General Project. She has also contributed to the Guangzhou Clinical Characteristic Technology Construction Project, focusing on the development of innovative brachytherapy techniques for cervical cancer treatment using multi-channel vaginal applicators.

Professor Huang’s dedication to advancing radiation oncology is further evidenced by her practical innovations, including holding a utility model patent. Her work continues to push the boundaries of cancer treatment, particularly in the realm of gynecological malignancies, making her a key figure in the field of radiation oncology in China.

Comprehensive treatment (eg., chemoradiotherapy,immunotherapy and brachytherapy) and relevant translational research for gynecologic tumor (such as: cervical cancer, endometrial cancer and carcinoma of vulva)

09/2017-06/2019, Medical Doctor,Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

09/2011-09/2017, Bachelor, SunYat-sen University, Guangzhou, China

1、Huang XD#, Huo LQ#, Xiao BB#, Ouyang Y#, Chen FP, Li JY, Zheng XP, Wei DH, Wu YZ, Zhang RH, Cao XP*, Kang TB*, Gao Y*. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. Cell Death Differ. 2023 Nov 25.（IF：12.4）

2、Huang XD#, Chen K#, Shi L#, Luo YS#, Ou-Yang Y, Li JY, Huo LQ, Huang L, Chen FP*, Cao XP*. Construction of refined staging classification systems integrating FIGO/T-categories and corpus uterine invasion for non-metastatic cervical cancer. Cancer Med. 2023 Jul;12(14):15079-15089. (IF:4.0)

3、Huang XD#, Huo LQ#, Luo YS#, Chen K, Li JY, Shi L, Huang L, Cao XP, Ou-Yang Y*, Chen FP*. Clinical utility of pretreatment serum squamous cell carcinoma antigen for prognostication and decision-making in patients with early-stage cervical cancer. Ther Adv Med Oncol. 2023 Apr 1;15:17588359231165974. (IF:4.9)

4、Gao Y#, Zheng XP#, Chang BY#, Lin YJ#, Huang XD#, Wang W#, Ding SR, Zhan WX, Wang S, Xiao BB, Huo LQ, Yu YH, Chen YL, Gong R, Wu YZ, Zhang RH, Zhong L, Wang X, Chen QY, Gao S, Jiang ZF, Wei DH*, Kang TB*. Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. Cell Res. 2022 Dec;32(12):1086-1104. (IF:44.1)

5、Chen FP#, Huang XD#, Lv JW#, Wen DW#, Zhou GQ, Lin L, Kou J, Wu CF, Chen Y, Zheng ZQ, Li ZX, He XJ, Sun Y*. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer. 2020 May 15;126(10):2163-2173.  (IF:6.2)

6、Huang XD#, Li YC#, Chen FP#, Zheng WH#, Zhou GQ, Lin L, Hu J, He WJ, Zhang LL, Kou J, Ma J, Zhang WD, Qi ZY, Sun Y*. Evolution and Dosimetric Analysis of Magnetic Resonance Imaging-Detected Brain Stem Injury After Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):124-131.(IF:7.0)

7、Huang XD#, Zhou GQ#, Lv JW#, Zhou HQ#, Zhong CW, Wu CF, Zheng ZQ, He XJ, Peng L, Ma J, Sun Y*. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. Radiother Oncol. 2018 Nov;129(2):389-395. (IF:5.7)

8、Lv JW#, Chen YP#, Huang XD#, Zhou GQ#, Chen L, Li WF, Tang LL, Mao YP, Guo Y, Xu RH, Ma J, Sun Y*. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer. 2017 Sep 15;123(18):3540-3549. (IF:6.2)

9、Lv JW#, Huang XD#, Chen YP#, et al. A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry. Cancer Research and Treatment. 2018,50(2):324-334.(IF:4.6)

10、Zhang, Yaxiong#; Zhang, Zhonghan#; Huang, Xiaodan#; Kang, Shiyang; Chen,Gang; Wu, Manli; Miao, Siyu; Huang, Yan; Zhao, Hongyun*; Zhang, Li*  Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials , Clinical Lung Cancer, 2017, 18(5): E333-E340. (IF:3.6)